Premium
Erasca Inc (ERAS)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -3.42205323194 | 2.63 | 2.67 | 2.39 | 1767094 | 2.51259239 | CS |
| 4 | -0.08 | -3.0534351145 | 2.62 | 3.3 | 2.39 | 1395537 | 2.79886743 | CS |
| 12 | -0.17 | -6.27306273063 | 2.71 | 3.305 | 2.39 | 1461434 | 2.78397446 | CS |
| 26 | 0.5 | 24.5098039216 | 2.04 | 3.45 | 2.01 | 1962340 | 2.75714982 | CS |
| 52 | 0.57 | 28.9340101523 | 1.97 | 3.45 | 1.64 | 1587920 | 2.55455809 | CS |
| 156 | -12.1 | -82.650273224 | 14.64 | 16.005 | 1.51 | 1055991 | 3.92840752 | CS |
| 260 | -13.36 | -84.0251572327 | 15.9 | 24.47 | 1.51 | 973715 | 4.70497325 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
